§ 20-A §6307 — Possession, prescription, administration and distribution of naloxone hydrochloride or another opioid overdose-reversing medication

Maine § 20-A §6307

• Jurisdiction: Maine
• Title 20-A: EDUCATION
• Part 3: ELEMENTARY AND SECONDARY EDUCATION
• Ch. 223: HEALTH, NUTRITION AND SAFETY

Text

1.
Definitions.
As used in this section, unless the context otherwise indicates, the following terms have the following meanings.
2.
Collaborative practice agreement; adoption authorized.
A school administrative unit or an approved private school may authorize adoption of a collaborative practice agreement for the purposes of stocking, possessing and administering naloxone hydrochloride or another opioid overdose-reversing medication as provided under this section. The administration of naloxone hydrochloride or another opioid overdose-reversing medication in accordance with this section is not the practice of medicine.
3.
Collaborative practice agreement; authority.
A collaborative practice agreement permits a physician licensed in this State or school health advisor to prescribe naloxone hydrochloride or another opioid overdose-reversing medication and direct a school nurse to administer naloxone hydrochloride or another opioid overdose-reversing medication in good faith to any student, staff member or visitor experiencing an apparent opioid overdose during school or a school-sponsored activity or otherwise on school grounds. Pursuant to a collaborative practice agreement, a physician licensed in this State or school health advisor may authorize the school nurse during school or a school-sponsored activity or otherwise on school grounds to designate designated school personnel to administer naloxone hydrochloride or another opioid overdose-reversing medication if the school nurse is not present when a student, staff member or visitor experiences a suspected opioid overdose.
4.
Collaborative practice agreement; terms and provisions.
A collaborative practice agreement must include the following information:
5.
Use of naloxone hydrochloride or another opioid overdose-reversing medication without a collaborative practice agreement.
If a collaborative practice agreement has not been adopted pursuant to subsection 2, the governing body of a school administrative unit or an approved private school may authorize a school nurse or other licensed health care professional whose scope of practice includes administration of naloxone hydrochloride or another opioid overdose-reversing medication to:
6.
Manufacturer or supplier arrangement.
A school administrative unit or an approved private school may enter into an arrangement with a manufacturer of naloxone hydrochloride or another opioid overdose-reversing medication or a 3rd-party supplier of naloxone hydrochloride or another opioid overdose-reversing medication to obtain naloxone hydrochloride or another opioid overdose-reversing medication at fair market prices, reduced prices or no cost.
7.
Purchase from licensed pharmacies.
A collaborative practice agreement under this section may provide that a school administrative unit or an approved private school may purchase naloxone hydrochloride or another opioid overdose-reversing medication from a pharmacy licensed in this State.
8.
Guidelines.
By January 1, 2022, and as needed after that date, the department in consultation with the Department of Health and Human Services shall develop and make available to all schools guidelines for the management of opioid overdose during school or a school-sponsored activity or otherwise on school grounds. The guidelines must include, but are not limited to:

Legislative History

PL 2021, c. 115, §1 (NEW). PL 2023, c. 161, §2 (AMD).